90158-62-6

Usage

Uses

Used in Pharmaceutical Development:
2-CYANO-N-THIAZOL-2-YL-ACETAMIDE is used as a pharmaceutical intermediate for its potential medicinal properties, contributing to the development of new drugs for the treatment of various diseases and disorders.
Used in Chemical Research:
In the field of chemical research, 2-CYANO-N-THIAZOL-2-YL-ACETAMIDE is employed as a research compound to explore its chemical properties and potential applications in the synthesis of other organic compounds.
Used in Synthesis of Organic Compounds:
2-CYANO-N-THIAZOL-2-YL-ACETAMIDE is utilized as a key intermediate in the synthesis of a variety of organic compounds, highlighting its versatility and importance in organic chemistry.

InChI:InChI=1/C6H5N3OS/c7-2-1-5(10)9-6-8-3-4-11-6/h3-4H,1H2,(H,8,9,10)

Upstream product

• 96-50-4 2-thiazolylamine 
• 105-56-6 ethyl 2-cyanoacetate 
• 372-09-8 cyanoacetic acid 
• 36140-83-7 1-cyanoacetyl-3,5-dimethylpyrazole 

Downstream Products

• 1006694-45-6 (2E)-2-cyano-3-phenyl-N-(1,3-thiazol-2-yl)prop-2-enamide 
• 953390-01-7 (phenylhydrazono)-N-(thiazol-2-yl)-2-cyanoacetamide 
• 1259321-80-6 6-amino-2-oxo-4-phenyl-1-(thiazol-2-yl)-1,2-dihydropyridine-3,5-dicarbonitrile 
• 1259321-79-3 4-amino-5-benzoyl-2-(phenylamino)-N-(thiazol-2-yl)thiophene-3-carboxamide 
• 1259321-78-2 5-(1-cyano-2-oxo-2-(thiazol-2-ylamino)ethylidene)-N,4-diphenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxamide 
• 1259321-81-7 6-hydroxy-2-oxo-4-phenyl-1-(thiazol-2-yl)-1,2-dihydropyridine-3,5-dicarbonitrile 
• 1259321-75-9 3-acetyl-5-amino-1-phenyl-N-(thiazol-2-yl)-1H-pyrazole-4-carboxamide 
• 1259321-76-0 5-amino-N₃-phenyl-N₄-(thiazol-2-yl)-1-(p-tolyl)-1H-pyrazole-3,4-dicarboxamide 

Relevant academic research and scientific papers

Synthesis, cytotoxic characterization, and SAR study of imidazo[1,2-b]pyrazole-7-carboxamides

The synthesis and in vitro cytotoxic characteristics of new imidazo[1,2-b]pyrazole-7-carboxamides were investigated. Following a hit-to-lead optimization exploiting 2D and 3D cultures of MCF-7 human breast, 4T1 mammary gland, and HL-60 human promyelocytic leukemia cancer cell lines, a 67-membered library was constructed and the structure–activity relationship (SAR) was determined. Seven synthesized analogues exhibited sub-micromolar activities, from which compound 63 exerted the most significant potency with a remarkable HL-60 sensitivity (IC50 = 0.183 μM).

Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity

With the aim to identify small molecules able to disrupt PA-PB1 subunits interaction of influenza virus (flu) RNA-dependent RNA polymerase, and based on previous structural and computational information, in this paper we have designed and synthesized a new series of cycloheptathiophene-3-carboxamide (cHTC) derivatives. Their biological evaluation led to highlight important structural insights along with new interesting compounds, such as the 2-hydroxybenzamido derivatives 29, 31, and 32, and the 4-aminophenyl derivative 54, which inhibited viral growth in the low micromolar range (EC50 = 0.18–1.2 μM) at no toxic concentrations (CC50 > 250 μM). This study permitted to obtain among the most potent anti-flu compounds within the PA-PB1 interaction inhibitors, confirming the cHTC scaffold as particularly suitable to achieve innovative anti-flu agents.

Utility of cyanoacetamides as precursors to pyrazolo-[3,4-d]pyrimidin-4-ones, 2-aryl-6-substituted 1,2,3-triazolo-[4,5-d]pyrimidines and pyrazolo[1,5-a]pyrimidine-3-carboxamides

Cyanoacetamides (7a-c) were prepared via reacting cyanoacetic acid (5) with amines in the presence of acetic anhydride. Compounds (7a-c) coupled with benzenediazonium chloride to yield the phenylhydrazones (8a-c). These reacted with chloroacetonitrile to yield aminopyrazolecarboxamides (11a-c). Reaction of (8a,b) with hydroxylamine hydrochloride in DMF in presence of anhydrous sodium acetate afforded the amino-1,2,3-triazolecarboxamides (36a,b). Also compounds (7a-c) reacted with dimethylformamide dimethylacetal (DMFDMA) to yield the enamines (9a-c) which react with hydrazine hydrate to afford the aminopyrazoles (16a-c). Compounds (16) and (36) reacted with DMFDMA to yield the title heterocyclic derivatives.

3-PHENYL-N- ((1, 3, 4) THIADIAZOL-2-YL) -ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ESTROGEN-RELATED RECEPTORS FOR THE TREATMENT OF E.G. CANCER, RHEUMATOID ARTHRITIS OR NEUROLOGICAL DISORDERS

Compounds of formula (I) are provided as well as compositions and methods of using compounds of formula (I) for modulating the activity of the estrogen-related receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder related to the activity of the estrogen-related receptor. Considering the wide range of activity of the nuclear hormone receptor ERRα, the compounds described herein which are capable of modulating ERRα activity, are useful for treating a range of disease states including cancer, diabetes, obesity, hyperlipidermia, arthritis, atherosclerosis, osteoporosis, anxiety, depression, Parkinson’s disease and Alzheimer’s disease. Formula (I). The substituents are defined in the claims.

Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor α

The estrogen-related receptor α (ERRα) is an orphan receptor belonging to the nuclear receptor superfamily. The physiological role of ERRα has yet to be established primarily because of lack of a natural ligand. Herein, we describe the discovery of the fi